title: Bone marrow transplantation for Fanconi anemia. Adjustment of the dose of cyclophosphamide for preconditioning.
abstract: OBJECTIVE
  Five patients with Fanconi anemia have been treated by bone marrow transplantation.
  
  
  METHODS
  They were conditioned with cyclophosphamide (CY) (20-150 mg/kg), antilymphocyte globulin, and thoracoabdominal irradiation (4-6 Gy). The dose of CY for preconditioning was adjusted individually, based on the in vitro effect of CY metabolites on the chromosomes of patients with Fanconi anemia. Four patients received marrow from human leukocyte antigen (HLA)-identical siblings, and one received marrow from his HLA phenotypically identical father.
  
  
  RESULTS
  All patients achieved engraftment, and acute graft-versus-host disease (GVHD) grade II or more was not observed. Three developed chronic GVHD. All patients are surviving 2-5 years after grafting, with hematological improvement.
  
  
  CONCLUSIONS
  These results indicate that the individual dose adjustment of CY used for preconditioning may prevent graft failure and severe acute GVHD.
authors.affiliation: Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yabe
authors.forename: H
authors.initials: H
authors.lastname: Yabe
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: T
authors.initials: T
authors.lastname: Hinohara
authors.forename: Y
authors.initials: Y
authors.lastname: Oh
authors.forename: K
authors.initials: K
authors.lastname: Hattori
authors.forename: K
authors.initials: K
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Ohshima
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Kato
mesh_terms: D000741:Anemia, Aplastic / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D003520:Cyclophosphamide / Q000627:therapeutic use* / Q000633:toxicity; D005199:Fanconi Anemia / Q000097:blood / Q000628:therapy*; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008297:Male; D014019:Tissue Donors
chemical_list: D000961:Antilymphocyte Serum; D003520:Cyclophosphamide